Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987382 | 0.85 | PDE5A (0.42) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL4983757 | 0.82 | PDE1B (0.45) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL4986240 | 0.82 | PDE5A (0.40) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL4980044 | 0.77 | PDE5A (0.45) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL4981854 | 0.76 | PDE5A (0.51) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL25921904 | 0.73 | KDM4E (0.46) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL4983982 | 0.71 | BCL2 (0.44) | KDM4E | |
| SCHEMBL4986822 | 0.70 | KMT2A (0.50) | PDE3BPDE3APDE5AKDM4EALDH1A1 | |
| SCHEMBL28619589 | 0.68 | PDGFRB (0.49) | KMT2A | |
| SCHEMBL4986725 | 0.68 | HRH4 (0.52) | KDM4EALDH1A1SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | claimed |
| EP-1841746-A1 | SUBSTITUTED 2-AMINO-QUINAZOLIN-4-ON COMPOUNDSFOR USE IN THE TREATMENT OF CNS DISORDERS, PAIN, STROKE, ADDICITION AND EPILEPSY, THEIR PREPARATION AND USE AS INTERMEDIATES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-10 | — | — | EP | claimed |
| WO-2006072588-A1 | SUBSTITUTED 2-AMINO-QUINAZOLIN-4-CN COMPOUNDS FOR USE IN THE TREATMENT OF CNS DISORDERS, PAIN, STROKE, ADDICTION AND EPILEPSY, THEIR PREAPARATION AND USE AS INTERMEDIATES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2006-07-13 | — | — | WO | claimed |
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| EP-1841746-A1 | SUBSTITUTED 2-AMINO-QUINAZOLIN-4-ON COMPOUNDSFOR USE IN THE TREATMENT OF CNS DISORDERS, PAIN, STROKE, ADDICITION AND EPILEPSY, THEIR PREPARATION AND USE AS INTERMEDIATES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006072588-A1 | SUBSTITUTED 2-AMINO-QUINAZOLIN-4-CN COMPOUNDS FOR USE IN THE TREATMENT OF CNS DISORDERS, PAIN, STROKE, ADDICTION AND EPILEPSY, THEIR PREAPARATION AND USE AS INTERMEDIATES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | CNR2, CNR1, GRIN2C | PDE3B 845/4885PDE3A 1098/4885PDE5A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.